Toward a More Proactive Health Care System
Dr. Alexandra Bause explains how today’s reactive approach provides sick care, not health care—and how biopharma strives to change that.
Dr. Alexandra Bause explains how today’s reactive approach provides sick care, not health care—and how biopharma strives to change that.
BCG’s second annual report reviews the growth of new drug modalities over the past year and addresses the potential impact on the biopharmaceutical industry.
The US biosimilars market is experiencing strong growth as regulations evolve and physician confidence in these products grows. But market patterns are changing.
Even in a strong market, CROs are facing some longer-term challenges that could reshape the industry in the next five to ten years.
The cash generics market has the potential to become a $15 billion market by 2030. Here’s how incumbents and new entrants should prepare.
The Team B approach involves assembling an independent cross-functional team to conduct rapid reviews of launch plans and market conditions for new pharmaceutical products.
Biopharma companies can leverage new sources of patient data and technology to create more personalized patient experiences that have the potential to deliver better health outcomes.
This is a modal window.
The global biopharma company’s chief data and technology officer discusses its initiative to inject digital capabilities across the value chain and the importance of prioritizing patient outcomes.
This is a modal window.
Mike McDonnell explains how the global biotech is charting new paths to patients via Fit for Growth, its corporate transformation initiative.
This is a modal window.
Chief Digital and Technology Officer Lidia Fonseca explains how Pfizer is leveraging digital and data across the value chain and the biggest wins so far.
This is a modal window.
Hudson discusses the company’s commitment to reaching net zero emissions by 2045.
Personalization is a $2 trillion opportunity. BCG's new book offers a playbook for capturing your share of this personalization prize in the health care industry.
Learn More About Personalized
Benchmark Your Personalization Readiness Now
This is a modal window.
Health care companies can unlock AI's potential and drive sales growth by prioritizing change management—not just technology—says BCG’s Basir Mustaghni.
To thrive during turbulent economic times, health systems can learn from the aviation industry, which embraced novel diversification approaches to maintain revenue stability and improve profitability.
While digital, data, and AI have extraordinary potential to revolutionize our global health care systems, they have yet to deliver a transformative impact. How can the public and private sectors accelerate progress?
The latest technologies hold tremendous promise for health care, but they also pose significant challenges. Not all organizations are prepared to take advantage of the tech trends.
The number of ESG regulations continues to grow. Leading medtech companies are going beyond merely complying to gain competitive advantage.
By developing products for a broader base of patients and markets, medtech companies can improve health outcomes, generate business advantages, and contribute to healthier societies overall.
Most environmental waste generated by the health care sector comes from medtech products. For a sector focused on improving quality of life, reducing waste and greenhouse gases is imperative.
To realize the promise and potential for GenAI, medtech executives must make swift and targeted efforts.
Extreme weather events such as cyclones and floods will drive increases in the incidence of sickness and death from malaria in Africa, according to a new study.
BCG conducted a study of more than 70 organizations—including philanthropies, multilateral development banks, government agencies, nongovernmental organizations, private sector actors, and others—to understand how key stakeholders are approaching the climate-health challenge.
This is a modal window.
Too often is it taken for granted that the environment is a massive determinant of human well-being. Putting health at the center of our climate discussions is critical.
The biopharma industry faces demands for more action to address health inequities. We provide a guide and tools to help companies integrate equity across the product lifecycle.